Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 9:8:679171.
doi: 10.3389/fmed.2021.679171. eCollection 2021.

Urinary Extracellular Vesicles for Renal Tubular Transporters Expression in Patients With Gitelman Syndrome

Affiliations

Urinary Extracellular Vesicles for Renal Tubular Transporters Expression in Patients With Gitelman Syndrome

Chih-Chien Sung et al. Front Med (Lausanne). .

Abstract

Background: The utility of urinary extracellular vesicles (uEVs) to faithfully represent the changes of renal tubular protein expression remains unclear. We aimed to evaluate renal tubular sodium (Na+) or potassium (K+) associated transporters expression from uEVs and kidney tissues in patients with Gitelman syndrome (GS) caused by inactivating mutations in SLC12A3. Methods: uEVs were isolated by ultracentrifugation from 10 genetically-confirmed GS patients. Membrane transporters including Na+-hydrogen exchanger 3 (NHE3), Na+/K+/2Cl- cotransporter (NKCC2), NaCl cotransporter (NCC), phosphorylated NCC (p-NCC), epithelial Na+ channel β (ENaCβ), pendrin, renal outer medullary K1 channel (ROMK), and large-conductance, voltage-activated and Ca2+-sensitive K+ channel (Maxi-K) were examined by immunoblotting of uEVs and immunofluorescence of biopsied kidney tissues. Healthy and disease (bulimic patients) controls were also enrolled. Results: Characterization of uEVs was confirmed by nanoparticle tracking analysis, transmission electron microscopy, and immunoblotting. Compared with healthy controls, uEVs from GS patients showed NCC and p-NCC abundance were markedly attenuated but NHE3, ENaCβ, and pendrin abundance significantly increased. ROMK and Maxi-K abundance were also significantly accentuated. Immunofluorescence of the representative kidney tissues from GS patients also demonstrated the similar findings to uEVs. uEVs from bulimic patients showed an increased abundance of NCC and p-NCC as well as NHE3, NKCC2, ENaCβ, pendrin, ROMK and Maxi-K, akin to that in immunofluorescence of their kidney tissues. Conclusion: uEVs could be a non-invasive tool to diagnose and evaluate renal tubular transporter adaptation in patients with GS and may be applied to other renal tubular diseases.

Keywords: Gitelman syndrome; hypokalemia; renal tubular disease; renal tubular transporters; urinary extracellular vesicles (exosomes).

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Characterization of urinary extracellular vesicles (uEVs) from healthy controls. (A) Screen shot from 1:2,000 diluted urine sample reveals a range of particle sizes by nanoparticle tracking analysis (NTA). (B) Concentration and size distribution of uEVs (0–150 nm diameter) by NTA were shown. The concentration is expressed as number of particles per ml. (C) uEVs particles were correlated strongly with urine creatinine (r2 for 0.81, P < 0.0001). (D) Transmission electron microscopy of uEVs was shown (scale bar 100 nm). (E) uEVs markers (AQP2, TSG101, NSE, and CD9) were assessed by immunoblotting. (F) Expression pattern of renal transporters including NHE3, NKCC2, NCC, p-NCC, ENaCβ, pendrin, ROMK, and Maxi-K from healthy controls was similar.
Figure 2
Figure 2
Renal Na+ and K+ associated transporters expression from urinary extracellular vesicles in patients with GS (n = 10) compared with healthy controls. (A) Immunoblotting of renal transporters (NHE3, NKCC2, NCC, p-NCC, ENaCβ, pendrin, ROMK, Maxi-K, and CD9). (B) Quantification of immunoblotting of NHE3, NKCC2, NCC, p-NCC, ENaCβ, pendrin, ROMK, Maxi-K, and CD9. Error bars, standard deviation. *P < 0.05, **P < 0.01.
Figure 3
Figure 3
Immunofluorescence of biopsied kidney tissues from another 3 representative GS patients (GS 1, GS 2, and GS 3) compared with the control kidney tissue. Renal transporters including NHE3, NKCC2, NCC, p-NCC, ENaCβ, pendrin, ROMK, Maxi-K were stained with green. AQP2 was stained with red for localization. Scale bar, 50 μm.
Figure 4
Figure 4
Renal transporters expression from urinary extracellular vesicles (uEVs) and immunofluorescence of biopsied kidney tissues from bulimic patients. (A) Immunoblotting of renal transporters (NHE3, NKCC2, NCC, p-NCC, ENaCβ, pendrin, ROMK, Maxi-K, and CD9) from uEVs in bulimic patients (n = 3) compared with healthy control. (B) Immunofluorescence of NHE3, NKCC2, NCC, p-NCC (green, right) and ENaCβ, pendrin, ROMK, Maxi-K (green, left) from one representative bulimia patient compared with the control. AQP2 was stained with red for localization. Scale bar, 50 μm.

References

    1. Blanchard A, Bockenhauer D, Bolignano D, Calò LA, Cosyns E, Devuyst O, et al. . Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. (2017) 91:24–33. 10.1016/j.kint.2016.09.046 - DOI - PubMed
    1. Simon DB, Nelson-Williams C, Bia MJ, Ellison D, Karet FE, Molina AM, et al. . Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet. (1996) 12:24–30. 10.1038/ng0196-24 - DOI - PubMed
    1. Lo Y-F, Nozu K, Iijima K, Morishita T, Huang C-C, Yang S-S, et al. . Recurrent deep intronic mutations in the SLC12A3 gene responsible for Gitelman's syndrome. Clin J Am Soc Nephrol. (2011) 6:630–9. 10.2215/CJN.06730810 - DOI - PMC - PubMed
    1. Vargas-Poussou R, Dahan K, Kahila D, Venisse A, Riveira-Munoz E, Debaix H, et al. . Spectrum of mutations in Gitelman syndrome. J Am Soc Nephrol. (2011) 22:693–703. 10.1681/ASN.2010090907 - DOI - PMC - PubMed
    1. Tseng MH, Yang SS, Hsu YJ, Fang YW, Wu CJ, Tsai JD, et al. . Genotype, phenotype, and follow-up in Taiwanese patients with salt-losing tubulopathy associated with SLC12A3 mutation. J Clin Endocrinol Metab. (2012) 97:E1478–82. 10.1210/jc.2012-1707 - DOI - PubMed